

# UPMC Health Plan

## JUXTAPID, KYNAMRO

### Prior Authorization Form

IF THIS IS AN URGENT REQUEST, please call UPMC Health Plan Pharmacy Services.

Otherwise, please return completed form to:

UPMC HEALTH PLAN PHARMACY SERVICES

PHONE 800-396-4139

FAX 412-454-7722

**PLEASE TYPE OR PRINT NEATLY. Incomplete responses may delay this request.**

<b>Office Contact:</b>		<b>Provider Specialty:</b>	
<b>Provider First Name:</b>		<b>Provider Last Name:</b>	
<b>Provider Phone:</b>		<b>Provider Fax:</b>	<b>Provider NPI #:</b>
<b>Patient Name:</b>	<b>Patient UPMC Health Plan ID Number:</b>	<b>Patient DOB:</b>	<b>Patient Age:</b>
<b>Drug Requested:</b> <input type="checkbox"/> Brand <input type="checkbox"/> Generic	<b>Strength:</b>	<b>Frequency:</b>	<b>Qty. Dispensed:</b>
<i>Generic equivalent drugs will be substituted for brand-name drugs unless you specifically indicate otherwise.</i>			
<input type="checkbox"/> New medication <input type="checkbox"/> Ongoing medication	<b>If ongoing, provide date started:</b>	<b>If medication is ongoing, did member show improvement while on therapy?</b>	<input type="checkbox"/> Yes <input type="checkbox"/> No
<b>Diagnosis:</b>			

### MEDICAL HISTORY

<b>Is the provider a clinical lipidologist?</b>		<input type="checkbox"/> Yes <input type="checkbox"/> No
<b>If no, was a clinical lipidologist consulted on the diagnosis and prescribing of the requested medication?</b>		<input type="checkbox"/> Yes <input type="checkbox"/> No
<b>Does the member have a diagnosis of Homozygous Familial Hypercholesterolemia?</b> ❖ Please provide chart documentation of the diagnosis, including how the diagnosis was made, rule out diagnoses, and any diagnostic testing or laboratory assessments completed.		<input type="checkbox"/> Yes <input type="checkbox"/> No
<b>Please indicate if the member has any of the following:</b> <input type="checkbox"/> Functional mutation(s) in both LDL receptor alleles or alleles known to affect LDL receptor functionality If so, please provide chart documentation of the diagnostic test. <input type="checkbox"/> Skin fibroblast LDL receptor activity less than 20% of normal <input type="checkbox"/> Presence of cutaneous and tendon xanthomas and corneal arcus If so, please provide age of onset: _____ <input type="checkbox"/> Both parents with documented history of untreated total cholesterol greater than 250mg/dL		
<b>Female members (Juxtapid requests only)</b>	<b>If the member is of childbearing potential, has she had a baseline (within 1 month) negative pregnancy test prior to initiation of therapy?</b> Please provide date of test: _____	<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Not applicable
	<b>If the member is of childbearing potential, is she currently using a medically acceptable method of contraception?</b>	<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Not applicable
<b>Did the member have baseline (within 1 month) transaminase, alkaline phosphatase, and bilirubin levels tested?</b> Please provide date of test: _____		<input type="checkbox"/> Yes <input type="checkbox"/> No
<b>Did the member have baseline (within 1 month) cholesterol levels tested?</b> Please provide date of test: _____ Please provide baseline levels: <input type="checkbox"/> Total cholesterol: _____ <input type="checkbox"/> LDL cholesterol: _____ <input type="checkbox"/> Triglycerides: _____		<input type="checkbox"/> Yes <input type="checkbox"/> No

**Please be sure to complete and include the 2<sup>nd</sup> page of this form.**

# KYNAMRO, JUXTAPID

## Page 2

Patient Name	Patient UPMC Health Plan ID Number	Patient DOB
--------------	------------------------------------	-------------

Please be sure to complete and include this page with the 1<sup>st</sup> page of this form

Does the member have moderate to severe hepatic impairment?	<input type="checkbox"/> Yes <input type="checkbox"/> No
Is the member on concomitant therapy with any moderate or strong inhibitors of CYP3A4 (such as amprenavir, aprepitant, atazanavir, ciprofloxacin, crizotinib, darunavir/ritonavir, diltiazem, erythromycin, fluconazole, fosamprenavir, imatinib, verapamil, boceprevir, clarithromycin, conivaptan, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, voriconazole)?	<input type="checkbox"/> Yes <input type="checkbox"/> No

Please list all medications the member has previously tried and failed or is currently using.

Medication Name	Strength	Frequency	Dates of Trial		List adverse reactions/side effects/reason for discontinuation
			Start Date	End Date	

Is this request for a reauthorization?  Yes  No

If yes, please provide the following documentation:

- Documentation showing member's disease has stabilized
- Documentation showing member's transaminase, alkaline phosphatase, and bilirubin levels are being monitored regularly. Please provide dates of all tests completed: \_\_\_\_\_
- Documentation of reduction in LDL level since starting treatment  
LDL levels: \_\_\_\_\_  
Dates of all tests completed: \_\_\_\_\_

Please provide any additional information that should be considered in the space below:
